Trial Profile
A Opened, Randomized, Multi-centered Phase II study on the efficacy and safety of CreaVax-HCC(Autologous Mature Dendritic Cells)in patients with hepatocellular carcinoma for comparing after a operation and/or non-operation therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-CreaGene (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors JW CreaGene
- 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by Clinical Research Information Service (CriS) - Republic of Korea.
- 31 Jul 2013 Planned end date added (30 Sep 2013) as reported by Clinical Research Information Service (CriS) - Republic of Korea.
- 31 Jul 2013 Status changed from completed to active, no longer recruiting as reported by Clinical Research Information Service (CriS) - Republic of Korea.